1-t-Butylamino-2-butanon | 59603-42-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-t-Butylamino-2-butanon
• 英文别名: 1-(Tert-butylamino)butan-2-one
• CAS: 59603-42-8
• 化学式: C₈H₁₇NO
• 分子量: 143.229
• InChiKey: QHBWZFDMTMEMHJ-UHFFFAOYSA-N

物化性质

• 沸点：
  181.8±23.0 °C(Predicted)
• 密度：
  0.859±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-溴丁醛 、 叔丁胺 在 水 作用下， 以 甲醇 为溶剂， 生成 1-t-Butylamino-2-butanon
  参考文献：
  名称：

  Regioselectivity in cyclization of 3-aza-1,5-diketones to 4,5-dehydro-3-piperidones

  摘要：

  DOI：

  10.1007/bf00922504

文献信息

• Compositions and methods for the treatment of cancer
  申请人：CELLIX BIO PRIVATE LIMITED

  公开号：US10858349B2

  公开（公告）日：2020-12-08

  The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII and, the methods for the treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases.

  本发明涉及这些化合物或其药用可接受的多晶型物、溶剂、对映体、立体异构体和水合物。包含有效量的式 I、式 II、式 III、式 IV、式 V、式 VI、式 VII 和式 VIII 化合物的药物组合物以及治疗癌症和传染性疾病的方法可配制成口服、口腔、直肠、局部、透皮、透粘膜、锭剂、喷雾剂、静脉注射、口服溶液、颊粘膜层片剂、肠外给药、糖浆或注射剂。这些成分可用于治疗癌症、肿瘤、感染和皮肤病。
• AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS
  申请人：Epizyme, Inc.

  公开号：US20170355712A1

  公开（公告）日：2017-12-14

  The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
  申请人：CELLIX BIO PRIVATE LIMITED

  公开号：US20190292171A1

  公开（公告）日：2019-09-26

  The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII and, the methods for the treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases.